Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Background: Neoadjuvant anti-PD-1 may improve outcomes for patients with resectable NSCLC and provides a critical window for examining pathologic features associated with response. Resections showing major pathologic response to neoadjuvant therapy, defined as ≤10% residual viable tumor (RVT), may predict improved long-term patient outcome. However, %RVT calculations were developed in the context of chemotherapy (%cRVT). An immune-related %RVT (%irRVT) has yet to be developed. Patients and methods: The first trial of neoadjuvant anti-PD-1 (nivolumab, NCT02259621) was just reported. We analyzed hematoxylin and eosin-stained slides from the post-treatment resection specimens of the 20 patients with non-small-cell lung carcinoma who underwent definitive surgery. Pretreatment tumor biopsies and preresection radiographic 'tumor' measurements were also assessed. Results: We found that the regression bed (the area of immune-mediated tumor clearance) accounts for the previously noted discrepancy between CT imaging and pathologic assessment of residual tumor. The regression bed is characterized by (i) immune activation-dense tumor infiltrating lymphocytes with macrophages and tertiary lymphoid structures; (ii) massive tumor cell death-cholesterol clefts; and (iii) tissue repair-neovascularization and proliferative fibrosis (each feature enriched in major pathologic responders versus nonresponders, P < 0.05). This distinct constellation of histologic findings was not identified in any pretreatment specimens. Histopathologic features of the regression bed were used to develop 'Immune-Related Pathologic Response Criteria' (irPRC), and these criteria were shown to be reproducible amongst pathologists. Specifically, %irRVT had improved interobserver consistency compared with %cRVT [median per-case %RVT variability 5% (0%-29%) versus 10% (0%-58%), P = 0.007] and a twofold decrease in median standard deviation across pathologists within a sample (4.6 versus 2.2, P = 0.002). Conclusions: irPRC may be used to standardize pathologic assessment of immunotherapeutic efficacy. Long-term follow-up is needed to determine irPRC reliability as a surrogate for recurrence-free and overall survival.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The histopathological features of response to neoadjuvant ICIs in patients with NSCLC have also been described111. These features include increased infiltration of lymphocytes and macrophages in tumours, presence of tertiary lymphoid structures, proliferative fibrosis and neovascularization.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [111]
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Self-citationMelanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Self-citationNeoadjuvant PD-1 Blockade in Resectable Lung Cancer
Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716078 · Cited by 2,099
Self-citationSTING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917
Hellmann, M. D., Chaft, J. E., William, W. N., Rusch, V., Pisters, K. M. W., Kalhor, N., Pataer, A., Travis, W. D., Swisher, S. G., & Kris, M. G. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70334-6 · Cited by 646
Self-citationLive to die another way: modes of programmed cell death and the signals emanating from dying cells
Fuchs, Y., & Steller, H. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3999 · Cited by 635
Jiménez-Sánchez, A., Memon, D., Pourpe, S., Veeraraghavan, H., Li, Y., Vargas, H. A., Gill, M. B., Park, K. J., Zivanovic, O., Konner, J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.025 · Cited by 458
Self-citationTertiary lymphoid structures, drivers of the anti‐tumor responses in human cancers
Dieu‐Nosjean, M., Giraldo, N. A., Kaplon, H., Germain, C., Fridman, W. H., & Sautès‐Fridman, C. (2016) · Immunological Reviews · doi:10.1111/imr.12405 · Cited by 417
Spranger, S., Luke, J. J., Bao, R., Zha, Y., Hernandez, K. M., Li, Y., Gajewski, A. P., Andrade, J., & Gajewski, T. F. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1609376113 · Cited by 399
Pataer, A., Kalhor, N., Correa, A. M., Raso, M. G., Erasmus, J. J., Kim, E. S., Behrens, C., Lee, J. J., Roth, J. A., Stewart, D. J., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318247504a · Cited by 374
Molecular Drivers of the Non–T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer
Sweis, R. F., Spranger, S., Bao, R., Paner, G. P., Stadler, W. M., Steinberg, G., & Gajewski, T. F. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0274 · Cited by 351
Pathological Complete Response and Accelerated Drug Approval in Early Breast Cancer
Prowell, T. M., & Pazdur, R. (2012) · New England Journal of Medicine · doi:10.1056/nejmp1205737 · Cited by 342
Provenzano, E., Bossuyt, V., Viale, G., Cameron, D., Badve, S., Denkert, C., MacGrogan, G., Penault-Llorca, F., Boughey, J., Curigliano, G., et al. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.74 · Cited by 293
Mature B cells accelerate wound healing after acute and chronic diabetic skin lesions
Sîrbulescu, R. F., Boehm, C. K., Soon, E., Wilks, M. Q., Ilieş, I., Yuan, H., Maxner, B., Chronos, N., Kaittanis, C., Normandin, M. D., et al. (2017) · Wound Repair and Regeneration · doi:10.1111/wrr.12584 · Cited by 122
Kumar, S., Calianese, D., & Birge, R. B. (2017) · Immunological Reviews · doi:10.1111/imr.12587 · Cited by 93
Yamane, Y., Ishii, G., Goto, K., Kojima, M., Nakao, M., Shimada, Y., Nishiwaki, Y., Nagai, K., Kohrogi, H., & Ochiai, A. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181c0a1f8 · Cited by 62
Histologic Assessment of Non–Small Cell Lung Carcinoma after Neoadjuvant Therapy
Liu‐Jarin, X., Stoopler, M. B., Raftopoulos, H., Ginsburg, M. E., Gorenstein, L. A., & Borczuk, A. (2003) · Modern Pathology · doi:10.1097/01.mp.0000096041.13859.ab · Cited by 51
A nonimmune function of T cells in promoting lung tumor progression
Green, J. A., Arpaia, N., Schizas, M., Dobrin, A., & Rudensky, A. Y. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20170356 · Cited by 46
Neoadjuvant Trials Could Speed Up Drug Approvals
Peres, J. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju072 · Cited by 4
Research works printed but not linked: 1
- Forde, 2018, Neoadjuvant PD-1 blockade in resectable lung cancer, N Engl J Med, 378, 1976, 10.1056/NEJMoa1716078 · DOI · Paper page
Cited by
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Forde, P. M., Spicer, J., Lu, S., Provencio, M., Mitsudomi, T., Awad, M. M., Felip, E., Broderick, S. R., Brahmer, J. R., Swanson, S. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2202170 · Cited by 2,825
Self-citationTertiary lymphoid structures in the era of cancer immunotherapy
Sautès-Fridman, C., Petitprez, F., Calderaro, J., & Fridman, W. H. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0144-6 · Cited by 1,884
Chalabi, M., Fanchi, L. F., Dijkstra, K. K., Van den Berg, J. G., Aalbers, A. G., Sikorska, K., Lopez-Yurda, M., Grootscholten, C., Beets, G. L., Snaebjornsson, P., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0805-8 · Cited by 1,417
Tertiary lymphoid structures in cancer
Schumacher, T. N., & Thommen, D. S. (2022) · Science · doi:10.1126/science.abf9419 · Cited by 1,142
Neoadjuvant checkpoint blockade for cancer immunotherapy
Topalian, S. L., Taube, J. M., & Pardoll, D. M. (2020) · Science · doi:10.1126/science.aax0182 · Cited by 1,001
Self-citation
Metadata
- Authors
- Cottrell, T. R., Thompson, E. D., Forde, P. M., Stein, J. E., Duffield, A. S., Anagnostou, V., Rekhtman, N., Anders, R. A., Cuda, J. D., Illei, P. B., Gabrielson, E., Askin, F. B., Niknafs, N., Smith, K. N., Velez, M. J., Sauter, J. L., Isbell, J. M., Jones, D. R., Battafarano, R. J., Yang, S. C., Danilova, L., Wolchok, J. D., Topalian, S. L., Velculescu, V. E., Pardoll, D. M., Brahmer, J. R., Hellmann, M. D., Chaft, J. E., Cimino-Mathews, A., & Taube, J. M.
- Affiliations
- Johns Hopkins University (US)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Taube, J.M.
- ORCID
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2018-08
- Volume
- 29
- Issue
- 8
- Pages
- 1853-1860
- ISSN
- 0923-7534 (ISSN-L)
- PMC
- PMC6096736
- OpenAlex
- W2867613812
- Cited by
- 592
- References
- 20
- Citations by year
- 2026: 80 · 2025: 97 · 2024: 91 · 2023: 101 · 2022: 82 · 2021: 58 · 2020: 55 · 2019: 20 · 2018: 7
- FWCI
- 13.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 450 d)
- Locations
- Annals of Oncology (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Sidney Kimmel Cancer Center (P30 CA006973, CA180950)
- National Cancer Institute (R01 CA142779)
- NIH (T32 CA193145, P30 CA008748)
- LCFA (#125133)
- KNS (CA121113)
- VEV
- LUNGevity Foundation
- V Foundation
- MacMillan Foundation
- International Association for the Study of Lung Cancer
- Memorial Sloan Kettering Cancer Center
- Research Institute Cancer Immunology Translational Cancer Research (SU2C-AACR-DT1012)
- American Association for Cancer Research
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- non-small cell lung cancer, residual viable tumor, nivolumab, tumor-infiltrating lymphocytes, tertiary lymphoid structures, cholesterol clefts, neovascularization, interobserver reproducibility, immunotherapy response assessment
- MeSH terms
- Antineoplastic Agents, Immunological, Ipilimumab, Nivolumab, Adult, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Feasibility Studies, Humans, Lung, Lung Neoplasms, Pneumonectomy, Prognosis, Reproducibility of Results, Treatment Outcome, Neoplasm, Residual, Neoadjuvant Therapy, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.